Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Rimcazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 9/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.97 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.97 |
| ▸ | SCARB1 | Q8WTV0 | 4/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | HTT | P42858 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimcazole SCHEMBL7410252 | 1.00 | SIGMAR1 (0.97) | SIGMAR1SCARB1MEN1KMT2AKDM4E | |
| Rimcazole SCHEMBL6257536 | 1.00 | SIGMAR1 (0.97) | SIGMAR1SCARB1MEN1KMT2AKDM4E | |
| Rimcazole SCHEMBL7411898 | 0.99 | MEN1 (1.00) | SIGMAR1SCARB1MEN1KMT2AKDM4E | |
| Rimcazole SCHEMBL3627653 | 0.99 | MEN1 (1.00) | SIGMAR1SCARB1MEN1KMT2AKDM4E | |
| Rimcazole SCHEMBL7411904 | 0.99 | MEN1 (1.00) | SIGMAR1SCARB1MEN1KMT2AKDM4E | |
| Rimcazole SCHEMBL29710924 | 0.98 | SIGMAR1 (1.00) | SIGMAR1SCARB1MEN1KMT2AKDM4E | |
| Rimcazole SCHEMBL31395408 | 0.98 | SIGMAR1 (1.00) | SIGMAR1SCARB1MEN1KMT2AKDM4E | |
| Rimcazole SCHEMBL99084 | 0.98 | SIGMAR1 (1.00) | SIGMAR1SCARB1MEN1KMT2AKDM4E | |
| Rimcazole SCHEMBL3237432 | 0.98 | SIGMAR1 (1.00) | SIGMAR1SCARB1MEN1KMT2AKDM4E | |
| Rimcazole SCHEMBL8873489 | 0.92 | MEN1 (0.83) | SIGMAR1SCARB1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2026-05-07 | — | — | US | claimed |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | THOMAS JEFFERSON UNIVERSITY | 2024-08-01 | — | — | US | claimed |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | UNIVERSITEIT GENT (BE) | 2021-06-15 | — | — | US | claimed |
| US-20200087730-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | UNIV DREXEL (US) | 2020-03-19 | — | — | US | claimed |
| US-20190328768-A1 | MOLECULAR ADJUVANTS FOR ENHANCED CYTOSOLIC DELIVERY OF ACTIVE AGENTS | UNIVERSITEIT GENT (BE) | 2019-10-31 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-2005079767-A2 | MEANS FOR MODULATION OF THE EFFECTS OF OPIOID-LIKE SUBSTANCES | Universitätsklinikum Münster (DE) | 2005-09-01 | — | — | WO | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-20040063612-A1 | Neuroprotective agents | CARBOMER, INC. | 2004-04-01 | — | — | US | claimed |
| US-20040019060-A1 | Sigma receptor ligands and their medical uses | SPRUCE BARBARA ANN (GB) | 2004-01-29 | — | — | US | claimed |
| JP-2003528916-A | — | — | 2003-09-30 | — | — | JP | claimed |
| EP-1267875-A1 | SIGMA RECEPTOR LIGANDS AND THEIR MEDICAL USES | Spruce, Barbara (GB) | 2003-01-02 | — | — | EP | claimed |
| WO-2001074359-A1 | SIGMA RECEPTOR LIGANDS AND THEIR MEDICAL USES | SPRUCE BARBARA (GB) | 2001-10-11 | — | — | WO | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019060-A1 | Sigma receptor ligands and their medical uses | TMEM97, SIGMAR1, GPR119 | SIGMAR1 2/4885HTR2A 88/4885HTR2C 57/4885 |
| US-20200087730-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885HTR2A 76/4885HTR2C 66/4885 |
| US-20240254561-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885HTR2A 76/4885HTR2C 66/4885 |
| US-11033572-B2 | Molecular adjuvants for enhanced cytosolic delivery of active agents | TLR9, PLA2G4C, STING1 | SIGMAR1 1389/4885HTR2A 3727/4885HTR2C 4597/4885 |
| US-20260125762-A1 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | IGF2BP3, RBM3, MORF4L1 | SIGMAR1 9/4885HTR2A 1336/4885HTR2C 796/4885 |
| US-20190328768-A1 | MOLECULAR ADJUVANTS FOR ENHANCED CYTOSOLIC DELIVERY OF ACTIVE AGENTS | TLR9, PLA2G4C, STING1 | SIGMAR1 1389/4885HTR2A 3727/4885HTR2C 4597/4885 |
| US-20040063612-A1 | Neuroprotective agents | GAP43, NLN, NOS3 | SIGMAR1 1036/4885HTR2A 1077/4885HTR2C 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.